BFH772 (VEGFR2 Inhibitor): Technical Guidance and Practical Protocols

What This Product Solves

BFH772 (CAS 890128-81-1) is a small-molecule VEGFR2 kinase inhibitor optimized for applications in research targeting VEGFR2-driven angiogenesis. It provides high selectivity (IC50 = 3 nM) for VEGFR2, with markedly reduced potency against related kinases, making it appropriate for experiments that require precise modulation of VEGFR2-mediated signaling without broad off-target effects (product_spec). Its role is well established in tumor angiogenesis research, where specific inhibition of VEGFR2 is essential for dissecting angiogenic mechanisms or evaluating anti-angiogenic strategies. BFH772 is most effective in workflows where organic solvent compatibility is acceptable and water solubility is not required.

Protocol Parameters

• Kinase inhibition assay | IC50: 3 nM | In vitro studies requiring precise VEGFR2 pathway modulation | High selectivity and potency for VEGFR2 enable targeted inhibition with minimal off-target activity | product_spec (link)
• Solubility (DMSO) | ≥53.4 mg/mL | Preparation of concentrated stock solutions for cell-based or enzyme assays | DMSO compatibility allows high-concentration stocks, but requires attention to DMSO percentage in final assay | product_spec (link)
• In vivo administration | Oral, formulation-dependent | Animal tumor model studies where oral VEGFR2 inhibition is required | Demonstrated efficacy in tumor growth and angiogenesis inhibition in animal models supports use in preclinical workflows | product_spec (link)
• Storage | -20°C (solid), avoid long-term solution storage | General lab storage for activity retention | Ensures compound stability and prevents degradation; long-term solution storage not recommended | product_spec (link)
• Assay suitability | Water-insoluble; use organic solvents | Assays tolerant to organic solvents (DMSO/ethanol) | Not suitable for protocols requiring aqueous solubility; select compatible assays | workflow recommendation (internal_article)

Workflow Setup and QC Checklist

For successful integration of BFH772 into angiogenesis research workflows, consider the following steps:

1. Compound Preparation: Dissolve BFH772 in DMSO or ethanol to prepare a concentrated stock (e.g., 10–50 mM), ensuring complete dissolution by gentle vortexing or brief sonication. Avoid water as a solvent due to insolubility (product_spec).
2. Storage and Handling: Store solid BFH772 at -20°C in a desiccated environment. Freshly prepare working solutions before use and avoid repeated freeze-thaw cycles for both solid and solution forms, as long-term solution storage is not recommended (product_spec).
3. Assay Setup: Carefully control the final DMSO or ethanol concentration in assay wells to avoid solvent-induced cytotoxicity. Typical final DMSO concentrations should not exceed 0.1–0.5% in cell-based assays (workflow recommendation).
4. Quality Control: Verify batch-specific purity (≥96%) via provided certificate of analysis. Confirm the absence of precipitation in working solutions before adding to biological assays.
5. Controls: Include solvent-only and, if appropriate, a known VEGFR2 inhibitor as experimental controls to validate assay responsiveness and specificity (internal_article).

Common Failure Modes and Fixes

• Incomplete dissolution: If BFH772 does not fully dissolve in DMSO or ethanol, increase agitation time or gently warm the solution (up to 37°C). Avoid water as a cosolvent.
• Precipitation in assay wells: Ensure compound is fully dissolved before dilution into media. Gradual dilution into pre-warmed media can minimize precipitation risk. Maintain DMSO below cytotoxic thresholds.
• Loss of activity over time: Prepare fresh working solutions immediately before use, as prolonged storage of BFH772 solutions can lead to degradation (product_spec).
• Unexpected off-target effects: If non-VEGFR2 effects are observed, confirm that assay systems do not depend on kinases where BFH772 shows residual activity (e.g., B-RAF, RET, TIE-2), and adjust controls accordingly (internal_article).

Scope and Limitations

BFH772 is highly effective as a VEGFR2 signaling pathway inhibitor in both in vitro and in vivo research, particularly where high selectivity and organic solvent compatibility are required. However, its use is not recommended for workflows that:

• Require water-soluble compounds, such as high-throughput screening platforms using aqueous buffers.
• Necessitate broad-spectrum kinase inhibition; BFH772 is not suitable for studies targeting multiple kinase pathways due to its selectivity profile.
• Demand long-term solution storage; the compound is only stable short-term in solution at recommended conditions (internal_article).

For information on workflows demanding water-soluble or broad-spectrum inhibitors, alternative compounds should be considered (internal_article).

Conclusion

BFH772 is a potent, selective anti-angiogenic agent for research applications requiring targeted VEGFR2 inhibition. Its solubility and stability characteristics demand attention to solvent selection and storage conditions, making it best suited for workflows compatible with DMSO or ethanol. Researchers should refer to batch-specific documentation and established protocol guidance to ensure optimal results. For further details or access to certificates of analysis, refer to the BFH772 (VEGFR2 inhibitor) product page from APExBIO.